Please wait while the formulary information is being retrieved.
SYNRIBO (OMACETAXINE MEPESUCCINATE)
- Accelerated phase chronic myelocytic leukemia
- Chronic phase chronic myeloid leukemia
3.5 mg subcutaneous solution
- Inject 1.25 mg/m2 by subcutaneous route 2 times per day for 7 consecutive days per 28 day cycle
Accelerated phase chronic myelocytic leukemia
- Inject 1.25 mg/m2 by subcutaneous route 2 times per day for 14 consecutive days per 28 day cycle
- Inject 1.25 mg/m2 by subcutaneous route 2 times per day for 7 consecutive days per 28 day cycle
Chronic phase chronic myeloid leukemia
- Inject 1.25 mg/m2 by subcutaneous route 2 times per day for 14 consecutive days per 28 day cycle
- Inject 1.25 mg/m2 by subcutaneous route 2 times per day for 7 consecutive days per 28 day cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- None
Contraindicated
- Anemia
- Gastrointestinal hemorrhage
- Increased risk of bleeding
- Infection
- Intracerebral hemorrhage
- Neutropenic disorder
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Diabetes mellitus
SYNRIBO (OMACETAXINE MEPESUCCINATE)
- Accelerated phase chronic myelocytic leukemia
- Chronic phase chronic myeloid leukemia
- Anemia
- Infection
- Lymphopenia
- Neutropenic disorder
- Thrombocytopenic disorder
- Diarrhea
- Fatigue
- Fever
- General weakness
- Injection site sequelae
- Nausea
More Frequent
Severe
Less Severe
- Diabetes mellitus
- Gastrointestinal hemorrhage
- Gout
- Hemorrhage
- Hypersensitivity drug reaction
- Seizure disorder
- Abdominal distension
- Acute abdominal pain
- Acute confusion
- Agitation
- Alopecia
- Angina
- Anorexia
- Arthralgias
- Back pain
- Bone pain
- Cataracts
- Conjunctivitis
- Cough
- Dehydration
- Depression
- Dizziness
- Dry skin
- Dysgeusia
- Dyspepsia
- Dyspnea
- Dysuria
- Earache
- Epistaxis
- Erythema
- Flu-like symptoms
- Flushing
- Gastroesophageal reflux disease
- Gingivitis
- Headache disorder
- Hyperglycemia
- Hyperhidrosis
- Insomnia
- Malaise
- Myalgias
- Nasal congestion
- Ocular pain
- Pain
- Palpitations
- Paresthesia
- Peripheral edema
- Petechiae
- Pruritus of skin
- Purpura
- Skin pigmentation enhancement
- Skin rash
- Sore throat
- Stomatitis
- Symptoms of anxiety
- Tinnitus
- Visual changes
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute coronary syndrome
- Bradycardia
- Hypertension
- Hypotension
- Intracerebral hemorrhage
- Tachycardia
- Ventricular premature beats
Less Severe
- Hematoma
- Muscle spasm
- Muscle weakness
- Musculoskeletal pain
- Rales
- Rhinorrhea
- Voice change
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Omacetaxine
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Omacetaxine
- Severity Level:
D
- Additional Notes: Insuff human data; potential for fetal harm; fetotoxic in mice at half mrhd.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Omacetaxine
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Accelerated phase chronic myelocytic leukemia | |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCr/ABl-positive, in relapse |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCr/ABl-negative, in relapse |
| Chronic phase chronic myeloid leukemia | |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| 0-9 | A-Z |
|---|---|
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.1 | Chronic myeloid leukemia, BCr/ABl-positive |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.10 | Chronic myeloid leukemia, BCr/ABl-positive, not having achieved remission |
| C92.12 | Chronic myeloid leukemia, BCr/ABl-positive, in relapse |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.2 | Atypical chronic myeloid leukemia, BCr/ABl-negative |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.20 | Atypical chronic myeloid leukemia, BCr/ABl-negative, not having achieved remission |
| C92.22 | Atypical chronic myeloid leukemia, BCr/ABl-negative, in relapse |
Formulary Reference Tool